Details

Autor(en) / Beteiligte

• Willmann, Jonas
• Appelt, Ane L.
• Balermpas, Panagiotis
• Baumert, Brigitta G.
• de Ruysscher, Dirk
• Hoyer, Morten
• Hurkmans, Coen
• Kaidar-Person, Orit
• Meattini, Icro
• Niyazi, Maximilian
• Poortmans, Philip
• Reynaert, Nick
• Tandini-Lang, Stephanie
• van der Linden, Yvette
• Nieder, Carsten
• Andratschke, Nicolaus

Titel

Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform

Ist Teil von

• Radiotherapy and oncology, 2023-12, Vol.189, p.109947-109947, Article 109947

Ort / Verlag

Elsevier B.V

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• [Display omitted] •First international survey on the patterns of care of re-irradiation.•Re-irradiation is predominantly employed in the brain, pelvis, and head and neck region.•Variable decision-making regarding minimum interval, contraindications and dose constraints.•Advanced radiation techniques and imaging are used, but dose accumulation methods diverge.•Prospective studies are needed to support evidence-based re-irradiation. Re-irradiation is an increasingly utilized treatment for recurrent, metastatic or new malignancies after previous radiotherapy. It is unclear how re-irradiation is applied in clinical practice. We aimed to investigate the patterns of care of re-irradiation internationally. A cross-sectional survey conducted between March and September 2022. The survey was structured into six sections, each corresponding to a specific anatomical region. Participants were instructed to complete the sections of their clinical expertise. A total of 15 multiple-choice questions were included in each section, addressing various aspects of the re-irradiation process. The online survey targeted radiation and clinical oncologists and was endorsed by the European Society for Radiotherapy and Oncology (ESTRO) and the European Organisation for Research and Treatment of Cancer (EORTC). 371 physicians from 55 countries across six continents participated. Participants had a median professional experience of 16 years, and the majority (60%) were affiliated with an academic hospital. The brain region was the most common site for re-irradiation (77%), followed by the pelvis (65%) and head and neck (63%). Prolonging local control was the most common goal (90–96% across anatomical regions). The most common minimum interval between previous radiotherapy and re-irradiation was 6–12 months (45–55%). Persistent grade 3 or greater radiation-induced toxicity (77–80%) was the leading contraindication. Variability in organs at risk dose constraints for re-irradiation was observed. Advanced imaging modalities and conformal radiotherapy techniques were predominantly used. A scarcity of institutional guidelines for re-irradiation was reported (16–19%). Participants from European centers more frequently applied thoracic and abdominal re-irradiation. Indications did not differ between academic and non-academic hospitals. This study highlights the heterogeneity in re-irradiation practices across anatomical regions and emphasizes the need for high-quality evidence from prospective studies to guide treatment decisions and derive safe cumulative dose constraints.